NO20055001L - Nytt difenylazetidinon med forbedrede fysiologiske egenskaper, fremgangsmate for fremstilling derav, legemiddel inneholdende forbindelsen og anvendelse derav - Google Patents

Nytt difenylazetidinon med forbedrede fysiologiske egenskaper, fremgangsmate for fremstilling derav, legemiddel inneholdende forbindelsen og anvendelse derav

Info

Publication number
NO20055001L
NO20055001L NO20055001A NO20055001A NO20055001L NO 20055001 L NO20055001 L NO 20055001L NO 20055001 A NO20055001 A NO 20055001A NO 20055001 A NO20055001 A NO 20055001A NO 20055001 L NO20055001 L NO 20055001L
Authority
NO
Norway
Prior art keywords
preparation
new
diphenylazetidinone
drug
containing compound
Prior art date
Application number
NO20055001A
Other languages
English (en)
Norwegian (no)
Inventor
Heiner Glombik
Hubert Heuer
Werner Kramer
Wendelin Frick
Hans-Ludwig Schaefer
Andreas Lindenschmidt
Gerhard Jaehne
Stefanie Flohr
Eric Galia
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20055001L publication Critical patent/NO20055001L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20055001A 2003-04-01 2005-10-27 Nytt difenylazetidinon med forbedrede fysiologiske egenskaper, fremgangsmate for fremstilling derav, legemiddel inneholdende forbindelsen og anvendelse derav NO20055001L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10314610A DE10314610A1 (de) 2003-04-01 2003-04-01 Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
PCT/EP2004/002690 WO2004087655A1 (de) 2003-04-01 2004-03-16 Neues diphenylazetidinon mit verbesserten physiologischen eigenschaften, verfahren zu dessen herstellung, diese verbindungen enthaltende arzneimittel und dessen verwendung

Publications (1)

Publication Number Publication Date
NO20055001L true NO20055001L (no) 2005-10-27

Family

ID=33103147

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055001A NO20055001L (no) 2003-04-01 2005-10-27 Nytt difenylazetidinon med forbedrede fysiologiske egenskaper, fremgangsmate for fremstilling derav, legemiddel inneholdende forbindelsen og anvendelse derav

Country Status (44)

Country Link
US (2) US7205290B2 (xx)
EP (2) EP1613589B1 (xx)
JP (1) JP2006522040A (xx)
KR (1) KR20050119180A (xx)
CN (2) CN100361970C (xx)
AR (1) AR043783A1 (xx)
AT (2) ATE386020T1 (xx)
AU (1) AU2004226287B2 (xx)
BR (1) BRPI0408920A (xx)
CA (1) CA2520689A1 (xx)
CL (1) CL43489B (xx)
CR (1) CR7995A (xx)
CY (2) CY1107398T1 (xx)
DE (3) DE10314610A1 (xx)
DK (2) DK1613589T3 (xx)
EC (1) ECSP056071A (xx)
ES (2) ES2298731T3 (xx)
GT (1) GT200400058A (xx)
HK (1) HK1087697A1 (xx)
HN (1) HN2004000109A (xx)
HR (1) HRP20050870A2 (xx)
JO (1) JO2493B1 (xx)
MA (1) MA27753A1 (xx)
ME (1) MEP41408A (xx)
MX (1) MXPA05010128A (xx)
MY (1) MY136269A (xx)
NI (1) NI200500164A (xx)
NO (1) NO20055001L (xx)
NZ (1) NZ542751A (xx)
PA (1) PA8599401A1 (xx)
PE (1) PE20050011A1 (xx)
PL (2) PL1862455T3 (xx)
PT (2) PT1862455E (xx)
RS (1) RS51146B (xx)
RU (1) RU2334737C2 (xx)
SA (1) SA04250154B1 (xx)
SI (2) SI1862455T1 (xx)
SV (1) SV2004001756A (xx)
TN (1) TNSN05244A1 (xx)
TW (1) TW200504009A (xx)
UA (1) UA80754C2 (xx)
UY (1) UY28253A1 (xx)
WO (1) WO2004087655A1 (xx)
ZA (1) ZA200506708B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE349425T1 (de) * 2000-12-21 2007-01-15 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
MX2008000115A (es) 2005-06-20 2008-03-18 Schering Corp Derivados de piperidina utiles como antagonistas de histamina h3.
US7067689B1 (en) 2005-07-08 2006-06-27 Microbia, Inc. Process for production of pentahydroxyhexylcarbamoyl alkanoic acids
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
DE102007029612A1 (de) * 2007-06-27 2009-01-08 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Pentahydroxyhexylcarbamoylundekan- säurebenzylester
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) * 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2009100258A1 (en) * 2008-02-05 2009-08-13 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical solid state forms
DE102008059772A1 (de) 2008-12-01 2010-06-02 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung eines Diphenylazetidinons
WO2009112203A1 (de) * 2008-03-14 2009-09-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur herstellung eines diphenylazetidinons
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10426480B2 (en) * 2015-04-29 2019-10-01 Covidien Lp Cutting ring assembly with rigid cutting member

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5756740A (en) * 1992-04-08 1998-05-26 Eastman Kodak Company Process for the preparation of binary sensitizing dyes
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
CN1158290C (zh) 1996-01-17 2004-07-21 诺沃挪第克公司 稠合1,2,4-噻二嗪与稠合1,4-噻嗪衍生物、其制备方法及用途
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
ID27511A (id) 1998-03-12 2001-04-12 Teijin Ltd Turunan-turunan benzofurilpiron
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
KR100452417B1 (ko) 1998-12-07 2004-10-12 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Ｇｌｐ-1의 유사체
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
BR0010126A (pt) 1999-04-28 2002-02-26 Aventis Pharma Gmbh Derivados de ácido tri-arìlico como ligandos receptores de ppar
BR0010605A (pt) 1999-04-28 2002-02-13 Aventis Pharma Gmbh Derivados ácidos de di-aril como ligantes de receptores ppar
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
AU773505B2 (en) 1999-06-18 2004-05-27 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
BR0012752A (pt) 1999-07-29 2002-04-02 Lilly Co Eli Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
ATE302754T1 (de) 1999-09-01 2005-09-15 Aventis Pharma Gmbh Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2001062266A2 (en) 2000-02-25 2001-08-30 Novo Nordisk A/S Use of dpp-iv inhibitors for the treatment of diabetes
CA2407538C (en) 2000-04-28 2007-01-09 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
EP1280777B1 (en) 2000-05-11 2005-11-23 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
HUP0004741A2 (hu) 2000-11-28 2002-12-28 Sanofi-Synthelabo Kémiai eljárás tiazolszármazékok előállítására és új intermedier
ATE349425T1 (de) * 2000-12-21 2007-01-15 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
DE10139416A1 (de) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6884812B2 (en) 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
JP4436129B2 (ja) 2001-08-31 2010-03-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
EP1862455A2 (de) 2007-12-05
MY136269A (en) 2008-09-30
EP1613589A1 (de) 2006-01-11
US7205290B2 (en) 2007-04-17
KR20050119180A (ko) 2005-12-20
ATE423766T1 (de) 2009-03-15
ZA200506708B (en) 2007-01-31
ES2298731T3 (es) 2008-05-16
CA2520689A1 (en) 2004-10-14
RS20050719A (xx) 2008-04-04
US20070197498A1 (en) 2007-08-23
SI1862455T1 (sl) 2009-06-30
RU2005133631A (ru) 2006-03-10
UY28253A1 (es) 2004-11-08
RU2334737C2 (ru) 2008-09-27
DE502004006195D1 (de) 2008-03-27
AU2004226287A1 (en) 2004-10-14
SI1613589T1 (sl) 2008-06-30
PT1862455E (pt) 2009-04-23
US7772429B2 (en) 2010-08-10
HN2004000109A (es) 2008-02-21
TNSN05244A1 (en) 2007-06-11
ATE386020T1 (de) 2008-03-15
NI200500164A (es) 2006-01-11
MA27753A1 (fr) 2006-02-01
ECSP056071A (es) 2006-01-27
EP1862455A3 (de) 2007-12-12
CL43489B (es) 2005-01-21
PE20050011A1 (es) 2005-02-28
CY1109055T1 (el) 2014-07-02
ES2322876T3 (es) 2009-06-30
MEP41408A (en) 2011-02-10
PL1613589T3 (pl) 2008-07-31
TW200504009A (en) 2005-02-01
AU2004226287B2 (en) 2010-03-18
EP1613589B1 (de) 2008-02-13
HK1087697A1 (en) 2006-10-20
SA04250154B1 (ar) 2007-10-29
CN1768034A (zh) 2006-05-03
BRPI0408920A (pt) 2006-03-28
AR043783A1 (es) 2005-08-10
US20050020563A1 (en) 2005-01-27
DK1613589T3 (da) 2008-06-09
CN100361970C (zh) 2008-01-16
JP2006522040A (ja) 2006-09-28
CR7995A (es) 2006-09-22
JO2493B1 (en) 2009-10-05
NZ542751A (en) 2007-05-31
CN101139306A (zh) 2008-03-12
GT200400058A (es) 2004-11-10
WO2004087655A1 (de) 2004-10-14
CY1107398T1 (el) 2012-12-19
SV2004001756A (es) 2004-11-18
PT1613589E (pt) 2008-03-27
PA8599401A1 (es) 2004-10-08
HRP20050870A2 (en) 2006-10-31
DE502004009059D1 (de) 2009-04-09
UA80754C2 (en) 2007-10-25
DK1862455T3 (da) 2009-06-02
RS51146B (sr) 2010-10-31
EP1862455B1 (de) 2009-02-25
MXPA05010128A (es) 2005-11-16
DE10314610A1 (de) 2004-11-04
PL1862455T3 (pl) 2009-07-31

Similar Documents

Publication Publication Date Title
NO20055001L (no) Nytt difenylazetidinon med forbedrede fysiologiske egenskaper, fremgangsmate for fremstilling derav, legemiddel inneholdende forbindelsen og anvendelse derav
IL173203A0 (en) Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
MY142830A (en) Propionic acid derivatives useful in the treatment of lipid disorders
NO20070176L (no) Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav
NO20065904L (no) Terapeutiske forbindelser
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20054852L (no) GFAT inhibitorer
UA84156C2 (ru) Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
NO20055766L (no) Positive modulatorer av nikotinacetylcholinreseptorer
RS20060015A (xx) Supstituisani derivati tiazol- benzoizotiazol dioksida, postupak za njihovu proizvodnju i njihovu primenu
NO20045222L (no) Benzosyrederivater som modulatorer av PPAR alfa og gamma
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
NO20053809L (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
NO20073176L (no) Nye medikamenter for behandling av luftveissykdommer
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
NO20054168L (no) Substituerte 3-(benzoylureido)-tiofenderivater, fremgangsmate for fremstilling og anvendelse derav
NO20063860L (no) 7-fenylamino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav samt deres anvendelse som legemidler
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom
NO20054389L (no) Cyckloalkyl-substituerte alkansyrederivater, fremgangsmate for fremstilling og anvendelse derav som legemiddel
WO2007104933A8 (en) Chemical compounds
NO20053805L (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
ATE391710T1 (de) Substituierte azetidinverbindungen als cyclooxigenase-1-cyclooxygenase-2-inhibitoren und deren herstellung und verwendung als medikament
EP1666472A4 (en) PHENYL ACETIC ACID DERIVATIVE, METHOD FOR THE PRODUCTION AND USE THEREOF
NO20045353L (no) Orto-substituerte benzosyrederivater for behandling av insulinresistens

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application